(Reuters) - Merck is nearing a roughly $10 billion deal to buy lung disease-focused biotech Verona Pharma, the Financial Times reported on Wednesday.
Verona Pharma stock soared over 18% on the news.
Merck would pay $107 per American depository share for Verona, the report said, citing three people familiar with the matter.
Reuters couldn't immediately verify the report.